Literature DB >> 3522031

Character of adverse effects of prophylactic lidocaine in the coronary care unit.

A W Rademaker, J Kellen, Y K Tam, D G Wyse.   

Abstract

Adverse effects of lidocaine therapy for proved or suspected myocardial infarction were evaluated for 48 hours in 285 patients arriving at the hospital within 6 hours of the onset of chest pain. More adverse effects occurred in patients receiving lidocaine (51%) than in those receiving placebo (16%; P less than 0.0001). Patients receiving lidocaine had more adverse effects in the first 12 hours as compared with the second 12 hours (50% vs. 19%; P less than 0.001). Patients without infarction who received lidocaine had more adverse effects than similarly dosed patients with infarction (64% vs. 39%; P = 0.002). The proportion of major adverse effects in those patients having any adverse effect was much greater in the last 24 hours as compared with the first 24 hours (86% vs. 32%; P = 0.006). All life-threatening problems (n = 5) occurred in the first 24 hours, most frequently in the first hour. Lidocaine levels were only weakly related to adverse effects potentially caused by lidocaine toxicity. We conclude that the adverse effects of prophylactic lidocaine have been understated in the past and may negate its antiarrhythmic efficacy.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3522031     DOI: 10.1038/clpt.1986.141

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  9 in total

1.  Lidocaïne test for easier and less time consuming assessment of liver function in several hepatic injury models.

Authors:  Dorra Ben Said; Ridha Ben Ali; Henda Ferchichi; Issam Salouage; Lobna Ouanes; Emna Gaïes; Sameh Trabelsi; Emna Kooli; Nadia Kourda; Jaouida Abdelmoula; Mohamed Lakhal; Anis Klouz
Journal:  Hepatol Int       Date:  2011-03-23       Impact factor: 6.047

Review 2.  Poisoning due to class 1B antiarrhythmic drugs. Lignocaine, mexiletine and tocainide.

Authors:  C P Denaro; N L Benowitz
Journal:  Med Toxicol Adverse Drug Exp       Date:  1989 Nov-Dec

3.  Quantification of three lidocaine metabolites and their conjugates.

Authors:  Y K Tam; J Ke; R T Coutts; D G Wyse; M R Gray
Journal:  Pharm Res       Date:  1990-05       Impact factor: 4.200

4.  Lidocaine induces endoplasmic reticulum stress-associated apoptosis in vitro and in vivo.

Authors:  Dae Young Hong; Kisang Kwon; Kyeong Ryong Lee; Young Jin Choi; Tae-Won Goo; Kweon Yu; Seung-Whan Kim; O-Yu Kwon
Journal:  Int J Mol Sci       Date:  2011-11-08       Impact factor: 5.923

5.  Lidocaine sensitizes the cytotoxicity of cisplatin in breast cancer cells via up-regulation of RARβ2 and RASSF1A demethylation.

Authors:  Kehan Li; Jianxue Yang; Xuechang Han
Journal:  Int J Mol Sci       Date:  2014-12-17       Impact factor: 5.923

Review 6.  Optimal antiarrhythmic drug therapy for electrical storm.

Authors:  Dan Sorajja; Thomas M Munger; Win-Kuang Shen
Journal:  J Biomed Res       Date:  2015-01-15

7.  Investigation of the Inhibitory Effect of Simvastatin on the Metabolism of Lidocaine Both in vitro and in vivo.

Authors:  Ying Wang; Qiu-Geng Ou-Yang; Wan-Li Huang; Huan-le Huang; Xin-Lei Zhuang; Qian-Meng Lin; Da-Li Zeng
Journal:  Drug Des Devel Ther       Date:  2020-05-06       Impact factor: 4.162

Review 8.  Prophylactic lidocaine for myocardial infarction.

Authors:  Arturo J Martí-Carvajal; Daniel Simancas-Racines; Vidhu Anand; Shrikant Bangdiwala
Journal:  Cochrane Database Syst Rev       Date:  2015-08-21

9.  Perioperative intravenous lignocaine infusion for postoperative pain control in patients undergoing surgery of the spine: protocol for a systematic review and meta-analysis.

Authors:  Ana Licina; Andrew Silvers
Journal:  BMJ Open       Date:  2020-10-13       Impact factor: 2.692

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.